Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration

IRVINE, Calif. & TEL AVIV, Israel–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and Ramot at Tel Aviv University Ltd., Tel Aviv University’s technology transfer company, today announced a research collaboration and license agreement for a preclinical anti-beta amyloid small molecu


Micropulse laser trabeculoplasty yields 75% success rate in glaucoma patients

BARCELONA — Micropulse laser trabeculoplasty yielded a success rate of 75% after treatment in patients with primary open angle glaucoma, according to a speaker. “The benefits of MLT [micropulse laser trabeculoplasty] are that [there are] no steroids, there is no scarring, there is no risk of infection, it is repeatable, it is a well-tolerated office procedure that can be performed under topical anesthesia, it has zero downtime, and it does not affect the success rates of future glaucoma surgeries,” Jacky W. Y. Lee, MBBS, MRCSEd, FRSCEd, FCOphthHK, FHKAM, said at the European Society of Cataract and Refractive Surgeons meeting.